NCT02734290: Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

NCT02734290
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active unstable central nervous system (CNS) metastases and/or carcinomatous meningitis that require treatment
https://ClinicalTrials.gov/show/NCT02734290

Comments are closed.

Up ↑